Vernon G., Baranova A., Younossi Z.M
P-LLY Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about retatrutide as a potential treatment for adults with obesity or overweight and knee osteoarthritis, potential efficacy and tolerability of retatrutide, and the timeline for future readouts, presentations, and other milestones relating to retatrutide and its clinical trials and reflects Lilly's current beliefs and expectations
Its time to get started on the path of losing weight and feeling confident about YOU again
May your peptide choices stay informed, your results stay visible, and your protocols stay optimized
list price sits at approximately $968 to $1,029 per month as of April 2026
Chemical Formula: CHNO Molecular Weight: 4845.444 g/mol CAS Number: 2381089-83-2 Purity: typically 9599%, verified through analytical testing Supplied as 60 mg lyophilized peptide in sealed vials Structural modifications: fatty acid conjugation and C-terminal amidation Intended for laboratory investigation of metabolic signaling pathways For research use only How is Retatrutide (60 mg) synthesized